ClinicalTrials.gg
TerminatedNCT00448539Updated Nov 22, 2019Results posted

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

A Phase 3 interventional study of Rufinamide in Refractory Partial Onset Seizures, sponsored by Eisai Inc.. Terminated at 27 sites in United States. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Non-randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Epilepsy by Eisai Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Epilepsy · Eisai Co., Ltd..

Enrollment
7th of 42
286 · median 83
Started
2007
with 1 other
Phase 3
17 of 51
none open now
Registered
11th of 51
by date

Among the 51 studies in Epilepsy by Eisai Co., Ltd., this one is the 7th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2007, is one of 17 in phase 3, and was the 11th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 51 studies in Epilepsy by Eisai Co., Ltd. is open now. The open studies under Epilepsy, anywhere →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 51 studies in Epilepsy by Eisai Co., Ltd. as a file.
02

Study summary

This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).

03

Conditions studied

  • Refractory Partial Onset Seizures

Browse trials for

Keywords

  • Refractory Partial Onset Seizures, epilepsy
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of Study E2080-A001-301 and full compliance with the inclusion and exclusion criteria for that study (excluding criteria that are related to seizure occurrences).
  2. Patient willing to participate and written consent signed by patient or legal guardian provided prior to entering this study or undergoing any study procedures. In addition, if the patient is unable to provide written and it is provided by a legal guardian, assent of the patient (if the patient is able) must also be obtained.
  3. Female patients of non- by reason of surgery, radiation, or menopause (at least one year post onset); female patients of childbearing potential who are using at least two approved methods of (such as an intrauterine device [IUD], implant, oral contraceptive, or barrier method plus spermicide). Use of a low-dose estrogen oral contraceptive alone will not be permitted. Female patients of childbearing potential must agree to continue to use two approved methods of contraception through the follow-up visit or for 30 days after their final dose of study medication, whichever is longer.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Discontinuation from Study E2080-A001-301 for any reason, before the termination of the study.
  2. Evidence of non-compliance with study drug or ongoing AED dosing during Study E2080-A001-301.
  3. Evidence of disease (cardiac, respiratory, gastrointestinal, hepatic (e.g., > 3x ), hematologic, renal, or psychiatric disease, etc.) that in the opinion of the Investigator could affect the patient's safety or trial conduct.
  4. Progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.
  5. History of alcohol abuse in the past 2 years.
  6. History of suicide attempt within the previous 10 years.
  7. Multiple drug allergies (dematological, heatological or organ toxicity) or more than one severe drug reaction.
  8. Concomitant use of felbamate or vigabatrin.
  9. Pregnancy.
  10. Clinically significant abnormality.
  11. All patients with a diagnosis of Congenital Short Syndrome. Patients with a family history of Congenital Short QT Syndrome may be excluded on the basis of the Investigator's clinical judgement.
  12. Presence of major active psychiatric disorder. Patients will be allowed who are taking a stable dose of selective serotonin reuptake inhibitor (SSRI) or mixed serotonin and norepinephrine uptake inhibitor antidepressant.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Rufinamide (Rufinamide During Core Study)

    Drug: Rufinamide

  • Experimental
    Rufinamide (Placebo During Core Study)

    Drug: Rufinamide

Interventions

  • Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).

    Also known as: E2080

06

What researchers measure

Primary outcomes

  1. Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase

    Seizure data was collected via patient diaries. "OL" refers to "open-label."

    Time frame: Baseline, Titration Phase (Days 1 to 18), Maintenance Phase

07

Results

Posted Dec 10, 2012
Limitations and caveats
This study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.

Participant flow

Participants who completed double-blind study E2080-A001-301 were allowed to enter in open-label extension Study 302. Participants completed a 12-day Transition Phase in Study 301 and received the same rufinamide maintenance dose that they achieved in Study 301 (Arm1), or transitioned from placebo to 3200 mg/day, beginning at 800 mg/day (Arm2).

Participant flow — Overall Study
MilestoneRufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)
Started134152
Completed00
Not completed134152
Withdrew: Medication non-compliance41
Withdrew: Protocol violation10
Withdrew: Request of the investigator or sponsor6754
Withdrew: Withdrawal by subject2024
Withdrew: Diary non-compliance10
Withdrew: Adverse event926
Withdrew: Lack of efficacy2740
Withdrew: Miscellaneous21
Withdrew: Change of meds23
Withdrew: Lost to follow-up13

Outcome measures

PrimaryPercentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase

Seizure data was collected via patient diaries. "OL" refers to "open-label."

Time frame:
Baseline, Titration Phase (Days 1 to 18), Maintenance Phase
Reported as:
Median · Percentage change
Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline Phase
Percentage changeRufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)
OL Titration Phase-35.65 (-100.0 to 1570.7)-45.10 (-100 to 518.2)
OL Maintenance Phase-30.95 (-100.0 to 246.5)-31.10 (-100 to 322.4)

Adverse events

Collected over From the date of first dose of rufinamide through study termination (up to 3 years and 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rufinamide (Rufinamide During Core Study)0/134 (0%)29/134 (21.6%)88/134 (65.7%)
Rufinamide (Placebo During Core Study)0/152 (0%)23/152 (15.1%)114/152 (75%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventRufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)
ConvulsionNervous system disorders5/1347/152
Status epilepticusNervous system disorders3/1340/152
Upper limb fractureInjury, poisoning and procedural complications2/1340/152
InfluenzaInfections and infestations0/1342/152
Postictal stateNervous system disorders0/1342/152
Myocardial infarctionCardiac disorders1/1340/152
PancreatitisGastrointestinal disorders1/1340/152
Upper Gastrointestinal HaemorrhageGastrointestinal disorders1/1340/152
VomitingGastrointestinal disorders1/1340/152
AstheniaGeneral disorders1/1340/152
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)
DizzinessNervous system disorders11/13443/152
ConvulsionNervous system disorders10/13420/152
NauseaGastrointestinal disorders12/13419/152
HeadacheNervous system disorders15/13417/152
VomitingGastrointestinal disorders14/13412/152
FatigueGeneral disorders6/13415/152
InsomniaPsychiatric disorders13/13410/152
SomnolenceNervous system disorders2/13414/152
SinusitisInfections and infestations12/1348/152
DepressionPsychiatric disorders12/1343/152

Baseline characteristics

Age, Customized
Age, Customized(participants)Rufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)Total
12 to <18 years61824
18 to <65 years123129252
>=65 years5510
Sex: Female, Male
Sex: Female, Male(Participants)Rufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)Total
Female6380143
Male7172143
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Rufinamide (Rufinamide During Core Study)Rufinamide (Placebo During Core Study)Total
Black71320
White115121236
Hispanic101121
Native American022
Asian/Pacific Islander224
Other033
08

Study locations

27 sites
  • University of South Alabama Medical Center
    Mobile, Alabama 36693, United States
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
  • Bradenton Research Center
    Bradenton, Florida 34205, United States
  • University of Florida, The Neuroscience Institute at Shands
    Jacksonville, Florida 32209, United States
  • Pediatric Neurologists of Palm Beach
    Loxahatchee Groves, Florida 33470, United States
  • Pediatric Neurosciences, PA
    Orlando, Florida 32835, United States
  • Bay Medical Center
    Panama City, Florida 32405, United States
  • Child Neurology Associates, PC
    Atlanta, Georgia 30342, United States
  • Southern Illinois University Neurology and Pharmacology
    Springfield, Illinois 62794-9643, United States
  • McFarland Clinic PC
    Ames, Iowa 50010-3014, United States
  • John Hopkins Hospital, Dept. of Neurology
    Baltimore, Maryland 21287, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Comprehensive Epilepsy Care Center for Children and Adults
    Chesterfield, Missouri 63017, United States
  • Dartmouth Medical School Neuroscience Center
    Lebanon, New Hampshire 03756-0001, United States
  • Five Towns Neuroscience Research
    Cedarhurst, New York 11516, United States
  • New York University Medical Centre, Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Weill Cornell Medical Center, Comprehensive Epilepsy Center
    New York, New York 10021, United States
  • Asheville Neurology Specialists
    Asheville, North Carolina 28806, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Medical University of Ohio at Toledo - Dept. of Neurology
    Toledo, Ohio, United States
  • Hospital of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104-4204, United States
  • University of Pennsylvania Medical Center-Department of Neurology
    Philadelphia, Pennsylvania 19104-4283, United States
  • University of Tennessee Health Sciences Center, Dept. of Neurology
    Memphis, Tennessee 38105, United States
  • Access Clinical Trials, Inc
    Nashville, Tennessee 37203, United States
  • Neurological Clinic of Texas, P.A.
    Dallas, Texas 75230, United States
  • Texas Tech University Health Sciences Center, Dept. of Neuropsychiatry
    El Paso, Texas 79905, United States
  • Fletcher Allen Healthcare
    Burlington, Vermont 05401, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2007 to primary completion in May 2010, 37 months.

Results were first posted in Dec 2012, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2007
First posted
Mar 19, 2007
StartActual
Mar 15, 2007
Primary completionActual
May 14, 2010
CompletionActual
May 14, 2010
Results first posted
Dec 10, 2012
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00448539
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 19, 2007
Start date
Mar 15, 2007
Primary completion
May 14, 2010
Completion
May 14, 2010
Results posted
Dec 10, 2012
Last update
Nov 22, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rufinamide

Start the discussion